-
Je něco špatně v tomto záznamu ?
Lower-Limb Lymphedema after Sentinel Lymph Node Biopsy in Cervical Cancer Patients
D. Cibula, M. Borčinová, S. Marnitz, J. Jarkovský, J. Klát, R. Pilka, A. Torné, I. Zapardiel, A. Petiz, L. Lay, B. Sehnal, J. Ponce, M. Felsinger, O. Arencibia-Sánchez, P. Kaščák, K. Zalewski, J. Presl, A. Palop-Moscardó, S. Tingulstad, I....
Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články
Grantová podpora
UNCE 204065
Univerzita Karlova v Praze
PROGRES Q28/LF1
Univerzita Karlova v Praze
NV19-03-00023
Czech Health research Council
NLK
Directory of Open Access Journals
od 2010
Free Medical Journals
od 2009
PubMed Central
od 2009
Europe PubMed Central
od 2009
ProQuest Central
od 2009-01-01
Open Access Digital Library
od 2009-01-01
Open Access Digital Library
od 2009-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2009
PubMed
34068399
DOI
10.3390/cancers13102360
Knihovny.cz E-zdroje
- Publikační typ
- časopisecké články MeSH
BACKGROUND: To prospectively assess LLL incidence among cervical cancer patients treated by uterine surgery complemented by SLN biopsy, without PLND. METHODS: A prospective study in 150 patients with stage IA1-IB2 cervical cancer treated by uterine surgery with bilateral SLN biopsy. Objective LLL assessments, based on limb volume increase (LVI) between pre- and postoperative measurements, and subjective patient-perceived swelling were conducted in six-month periods over 24-months post-surgery. RESULTS: The cumulative incidence of LLL at 24 months was 17.3% for mild LLL (LVI 10-19%), 9.2% for moderate LLL (LVI 20-39%), while only one patient (0.7%) developed severe LLL (LVI > 40%). The median interval to LLL onset was nine months. Transient edema resolving without intervention within six months was reported in an additional 22% of patients. Subjective LLL was reported by 10.7% of patients, though only a weak and partial correlation between subjective-report and objective-LVI was found. No risk factor directly related to LLL development was identified. CONCLUSIONS: The replacement of standard PLND by bilateral SLN biopsy in the surgical treatment of cervical cancer does not eliminate the risk of mild to moderate LLL, which develops irrespective of the number of SLN removed.
Department of Gynecologic Oncology Holycross Cancer Center 25 734 Kielce Poland
Department of Obstetrics and Gynecology Faculty Hospital Trencin 911 71 Trencin Slovakia
Department of Obstetrics and Gynecology Trondheim University Hospital 7030 Trondheim Norway
Gynecologic Oncology Unit La Paz University Hospital 28046 Madrid Spain
Gynecology Department Instituto Valenciano de Oncologia 46009 Valencia Spain
Serviço de Ginecologia Instituto Portugues de Oncologia do Porto 1099 023 Porto Portugal
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21017768
- 003
- CZ-PrNML
- 005
- 20210729104018.0
- 007
- ta
- 008
- 210726s2021 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/cancers13102360 $2 doi
- 035 __
- $a (PubMed)34068399
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Cibula, David $u Gynecologic Oncology Center, Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University and General University Hospital, 12000 Prague, Czech Republic
- 245 10
- $a Lower-Limb Lymphedema after Sentinel Lymph Node Biopsy in Cervical Cancer Patients / $c D. Cibula, M. Borčinová, S. Marnitz, J. Jarkovský, J. Klát, R. Pilka, A. Torné, I. Zapardiel, A. Petiz, L. Lay, B. Sehnal, J. Ponce, M. Felsinger, O. Arencibia-Sánchez, P. Kaščák, K. Zalewski, J. Presl, A. Palop-Moscardó, S. Tingulstad, I. Vergote, M. Redecha, F. Frühauf, C. Köhler, R. Kocián
- 520 9_
- $a BACKGROUND: To prospectively assess LLL incidence among cervical cancer patients treated by uterine surgery complemented by SLN biopsy, without PLND. METHODS: A prospective study in 150 patients with stage IA1-IB2 cervical cancer treated by uterine surgery with bilateral SLN biopsy. Objective LLL assessments, based on limb volume increase (LVI) between pre- and postoperative measurements, and subjective patient-perceived swelling were conducted in six-month periods over 24-months post-surgery. RESULTS: The cumulative incidence of LLL at 24 months was 17.3% for mild LLL (LVI 10-19%), 9.2% for moderate LLL (LVI 20-39%), while only one patient (0.7%) developed severe LLL (LVI > 40%). The median interval to LLL onset was nine months. Transient edema resolving without intervention within six months was reported in an additional 22% of patients. Subjective LLL was reported by 10.7% of patients, though only a weak and partial correlation between subjective-report and objective-LVI was found. No risk factor directly related to LLL development was identified. CONCLUSIONS: The replacement of standard PLND by bilateral SLN biopsy in the surgical treatment of cervical cancer does not eliminate the risk of mild to moderate LLL, which develops irrespective of the number of SLN removed.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Borčinová, Martina $u Gynecologic Oncology Center, Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University and General University Hospital, 12000 Prague, Czech Republic
- 700 1_
- $a Marnitz, Simone $u Department of Special Operative and Oncologic Gynaecology, Asklepios-Clinic Hamburg, 22763 Hamburg, Germany
- 700 1_
- $a Jarkovský, Jiří $u Data Analysis Department, Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, 62500 Brno, Czech Republic
- 700 1_
- $a Klát, Jaroslav $u Department of Obstetrics and Gynecology, University Hospital Ostrava, 70800 Ostrava Poruba, Czech Republic
- 700 1_
- $a Pilka, Radovan $u Department of Obstetrics and Gynecology, Faculty of Medicine and Dentistry, Palacky University, University Hospital Olomouc, 77900 Olomouc, Czech Republic
- 700 1_
- $a Torné, Aureli $u Unit of Gynecological Oncology, Institute Clinic of Gynaecology, Obstetrics, and Neonatology, Hospital Clinic-Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), University of Barcelona, 08036 Barcelona, Spain
- 700 1_
- $a Zapardiel, Ignacio $u Gynecologic Oncology Unit, La Paz University Hospital, 28046 Madrid, Spain
- 700 1_
- $a Petiz, Almerinda $u Serviço de Ginecologia, Instituto Portugues de Oncologia do Porto, 1099-023 Porto, Portugal
- 700 1_
- $a Lay, Laura $u Department of Gynaecology, Institute of Oncology Angel H Roffo University of Bueno s Aires, Buenos Aires C1417 DTB, Argentina
- 700 1_
- $a Sehnal, Borek $u Department of Obstetrics and Gynecology, First Faculty of Medicine, University Hospital Bulovka, Charles University, 18081 Prague, Czech Republic
- 700 1_
- $a Ponce, Jordi $u Department of Gynecology, Biomedical Research Institute of Bellvitge (IDIBELL), University Hospital of Bellvitge, University of Barcelona, 08908 Barcelona, Spain
- 700 1_
- $a Felsinger, Michal $u Department of Gynecology and Obstetrics, Faculty of Medicine, Masaryk University, 60177 Brno, Czech Republic
- 700 1_
- $a Arencibia-Sánchez, Octavio $u Departments of Gynecologic Oncology, University Hospital of the Canary Islands, 35016 Las Palmas de Gran Canaria, Spain
- 700 1_
- $a Kaščák, Peter $u Department of Obstetrics and Gynecology, Faculty Hospital Trencin, 911 71 Trencin, Slovakia
- 700 1_
- $a Zalewski, Kamil $u Department of Gynecologic Oncology, Holycross Cancer Center, 25-734 Kielce, Poland
- 700 1_
- $a Presl, Jiri $u Department of Obstetrics and Gynecology, Faculty of Medicine Pilsen, University Hospital in Pilsen and Charles University, 30460 Pilsen, Czech Republic
- 700 1_
- $a Palop-Moscardó, Alicia $u Gynecology Department, Instituto Valenciano de Oncologia (IVO), 46009 Valencia, Spain
- 700 1_
- $a Tingulstad, Solveig $u Department of Obstetrics and Gynecology, Trondheim University Hospital, 7030 Trondheim, Norway
- 700 1_
- $a Vergote, Ignace $u Department of Gynecology and Obstetrics, Leuven Cancer Institute, University Hospital Leuven, 3000 Leuven, Belgium
- 700 1_
- $a Redecha, Mikuláš $u Department of Gynaecology and Obstetrics, University Hospital, Comenius University, 814 99 Bratislava, Slovakia
- 700 1_
- $a Frühauf, Filip $u Gynecologic Oncology Center, Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University and General University Hospital, 12000 Prague, Czech Republic
- 700 1_
- $a Köhler, Christhardt $u Department of Special Operative and Oncologic Gynaecology, Asklepios-Clinic Hamburg, 22763 Hamburg, Germany
- 700 1_
- $a Kocián, Roman $u Gynecologic Oncology Center, Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University and General University Hospital, 12000 Prague, Czech Republic
- 773 0_
- $w MED00173178 $t Cancers $x 2072-6694 $g Roč. 13, č. 10 (2021)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34068399 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20210726 $b ABA008
- 991 __
- $a 20210729104017 $b ABA008
- 999 __
- $a ind $b bmc $g 1676415 $s 1138210
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 13 $c 10 $e 20210513 $i 2072-6694 $m Cancers $n Cancers $x MED00173178
- GRA __
- $a UNCE 204065 $p Univerzita Karlova v Praze
- GRA __
- $a PROGRES Q28/LF1 $p Univerzita Karlova v Praze
- GRA __
- $a NV19-03-00023 $p Czech Health research Council
- LZP __
- $a Pubmed-20210726
